216 related articles for article (PubMed ID: 17303473)
1. Metabolic actions of angiotensin receptor antagonists: PPAR-gamma agonist actions or a class effect?
Ernsberger P; Koletsky RJ
Curr Opin Pharmacol; 2007 Apr; 7(2):140-5. PubMed ID: 17303473
[TBL] [Abstract][Full Text] [Related]
2. [PPARgamma-activating properties of angiotensin receptor blockers].
Ando H; Fujimura A
Nihon Rinsho; 2006 Jul; 64 Suppl 5():498-501. PubMed ID: 16895217
[No Abstract] [Full Text] [Related]
3. HIV protease inhibitors activate the adipocyte renin angiotensin system.
Boccara F; Auclair M; Cohen A; Lefèvre C; Prot M; Bastard JP; Capeau J; Caron-Debarle M
Antivir Ther; 2010; 15(3):363-75. PubMed ID: 20516556
[TBL] [Abstract][Full Text] [Related]
4. New treatment strategies for patients with hypertension and insulin resistance.
Kurtz TW
Am J Med; 2006 May; 119(5 Suppl 1):S24-30. PubMed ID: 16563944
[TBL] [Abstract][Full Text] [Related]
5. Angiotensin-II receptor antagonists: their place in therapy.
Kirk JK
Am Fam Physician; 1999 Jun; 59(11):3140-8. PubMed ID: 10392595
[TBL] [Abstract][Full Text] [Related]
6. Human pharmacokinetic/pharmacodynamic profile of irbesartan: a new potent angiotensin II receptor antagonist.
Ruilope L
J Hypertens Suppl; 1997 Dec; 15(7):S15-20. PubMed ID: 9532516
[TBL] [Abstract][Full Text] [Related]
7. Irbesartan: review of pharmacology and comparative properties.
Adams MA; Trudeau L
Can J Clin Pharmacol; 2000; 7(1):22-31. PubMed ID: 10822210
[TBL] [Abstract][Full Text] [Related]
8. [Angiotensin-II receptor blockers].
Metelitsa VI
Ter Arkh; 1996; 68(8):64-7. PubMed ID: 9019837
[No Abstract] [Full Text] [Related]
9. Angiotensin II type 1 receptor blockers.
Burnier M
Circulation; 2001 Feb; 103(6):904-12. PubMed ID: 11171802
[No Abstract] [Full Text] [Related]
10. Angiotensin II receptor blockers: equal or preferred substitutes for ACE inhibitors?
Grossman E; Messerli FH; Neutel JM
Arch Intern Med; 2000 Jul; 160(13):1905-11. PubMed ID: 10888965
[No Abstract] [Full Text] [Related]
11. [Theoretical background of angiotensin II receptor blockade and its features in clinical pharmacology].
Winkler G; Jermendy G; Matos L
Orv Hetil; 2003 Sep; 144(36):1763-8. PubMed ID: 14579673
[TBL] [Abstract][Full Text] [Related]
12. Discovery of the bifunctional modulator of angiotensin II type 1 receptor (AT1R) and PPARγ derived from the AT1R antagonist, Fimasartan.
Choung W; Jung HJ; Nam EH; Yang D; Yoo B; Choi H; Lee BR; Park M; Jang SM; Lim JS; Kim KH; Chin J; Jung K; Lee G; Kim SH
Bioorg Med Chem Lett; 2018 Oct; 28(19):3155-3160. PubMed ID: 30177375
[TBL] [Abstract][Full Text] [Related]
13. [Pharmacological properties and clinical efficacy of the long-active angiotensin receptor blocker (ARB) irbesartan].
Ariyoshi Y; Mizumoto K
Nihon Yakurigaku Zasshi; 2009 May; 133(5):275-80. PubMed ID: 19443965
[No Abstract] [Full Text] [Related]
14. Angiotensin receptor antagonists.
Wong W; Howes L
Aust Fam Physician; 2000 Jul; 29(7):653-5, 658. PubMed ID: 10914449
[TBL] [Abstract][Full Text] [Related]
15. Telmisartan is a promising cardiometabolic sartan due to its unique PPAR-gamma-inducing property.
Yamagishi S; Takeuchi M
Med Hypotheses; 2005; 64(3):476-8. PubMed ID: 15617852
[TBL] [Abstract][Full Text] [Related]
16. Comparative angiotensin II receptor blockade in healthy volunteers: the importance of dosing.
Maillard MP; Würzner G; Nussberger J; Centeno C; Burnier M; Brunner HR
Clin Pharmacol Ther; 2002 Jan; 71(1):68-76. PubMed ID: 11823759
[TBL] [Abstract][Full Text] [Related]
17. A new class of antihypertensive therapy: angiotensin II receptor antagonists.
Ellis ML; Patterson JH
Pharmacotherapy; 1996; 16(5):849-60. PubMed ID: 8888079
[TBL] [Abstract][Full Text] [Related]
18. [Irbesartan: a new possibility in the treatment of hypertension].
Rapi J
Orv Hetil; 2002 May; 143(21):1187-92. PubMed ID: 12073539
[TBL] [Abstract][Full Text] [Related]
19. Angiotensin II type 1 receptor antagonists in animal models of vascular, cardiac, metabolic and renal disease.
Michel MC; Brunner HR; Foster C; Huo Y
Pharmacol Ther; 2016 Aug; 164():1-81. PubMed ID: 27130806
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic-pharmacodynamic relationships of three angiotensin II receptor antagonists in normal volunteers.
Burnier M; Buclin T; Biollaz J; Nussberger J; Waeber B; Brunner HR
Kidney Int Suppl; 1996 Jun; 55():S24-9. PubMed ID: 8743506
[No Abstract] [Full Text] [Related]
[Next] [New Search]
